Review finds uncertainty about molecular testing for urinary infections
Molecular tests detected more organisms and improved short-term symptoms in two trials, but their longer-term value remains unclear.
High evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Researchers reviewed English-language studies published from January 2023 through October 2025 involving adults and molecular testing methods such as PCR and next-generation sequencing. The review included observational studies and clinical trials, but the researchers said differences between the studies prevented a statistical combined analysis.
In the two randomized trials, PCR testing detected more possible infections than standard urine culture and helped guide antibiotic treatment associated with lower urinary symptoms over about 28 days. The review also identified concerns about frequent recurrence, possible detection of organisms that do not represent an active infection, and industry funding in several studies.
The question reviewed
The researchers conducted a systematic review of molecular diagnostic tests for urinary tract infections in adults. They searched PubMed, Ovid, and Embase for studies published from January 2023 through October 2025, screened 1,284 unique records, and included 12 full-text studies. The studies assessed methods including PCR, multiplex PCR, and next-generation sequencing, reporting diagnostic accuracy, changes in antibiotic selection or treatment, and symptom outcomes. The review followed PRISMA and Cochrane-related methods, was registered with PROSPERO, and assessed risk of bias. Because the studies differed substantially in design, populations, tests, and outcomes, the researchers performed a qualitative rather than statistical synthesis.
Key conclusions
The review authors reported that molecular tests, especially PCR-based tests, generally had higher sensitivity than standard urine culture. This means they detected more microbial material, but their lower specificity means that some detected organisms may not have represented a true symptomatic infection.
Two randomized clinical studies, involving 830 participants who were mostly women and older than 65, found that molecular-test results helped guide antibiotic treatment and were associated with reduced urinary symptoms over the short term, defined as 28 days. The review also reported that molecular tests more often identified mixed infections and less commonly detected organisms, although the included evidence for clinical benefit was limited. Only two studies assessed targeted or metagenomic next-generation sequencing.
The review found that recurrence was often high and that no included study assessed outcomes beyond 28 days. It also noted that the randomized trials and several prospective studies were funded by companies that developed the tests. These findings are associations or study-level results; they do not establish that molecular testing itself caused better outcomes for all patients.
Who this is relevant to
The findings apply most directly to adults similar to those represented in the included studies, who were mostly women and adults older than 65 in the two randomized trials. They should not automatically be extended to children, men-only populations, or people whose clinical circumstances differ from the reviewed studies. Because the review found limited long-term and real-world evidence, its results do not establish how molecular testing performs for every person with urinary symptoms or whether positive molecular results always indicate an active urinary infection.
The significance
Molecular testing may identify microbial material that standard urine culture misses and may provide results more quickly, but greater detection does not necessarily mean that a person has an infection requiring treatment. The review raises unresolved questions about overdiagnosis, unnecessary antibiotic exposure, recurrence, antibiotic resistance, cost, and how clinicians should interpret positive results alongside symptoms. The findings are relevant to human health because the included studies involved adults, but they do not establish the long-term benefits or harms of these tests in routine care.
Limitations & evidence assessment
The review included only 12 studies, and just two were randomized trials. The studies differed in their designs, patient groups, tests, and outcome measures, so the researchers could not perform a meta-analysis. Follow-up was short: no included study evaluated outcomes beyond 28 days, and recurrence was often high. Many studies had industry funding; eight of the 12 disclosed funding sources, with several supported by test manufacturers, which may have influenced study design or interpretation. The search was limited to English-language publications, one reviewer independently screened the initial records and extracted data, and evidence for next-generation sequencing was especially limited. The review also reported limited clinical outcome data and could not determine whether higher test sensitivity improves long-term outcomes or changes overall antibiotic use.
Why this evidence level: Systematic review aggregating primary studies with explicit methodology.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
World Journal of Urology · 2026 · DOI: 10.1007/s00345-026-06798-z
This human-focused review examines chronic subdural hematoma, a blood collection around the brain that is more common in older adults. It describes evidence for middle meningeal artery embolization, a procedure intended to reduce blood flow to the membrane that can help sustain the hematoma. The review presents the procedure as a possible addition to, or alternative for, surgery in selected high-risk patients—not as a universal replacement.
Researchers studied adults with pheochromocytoma or paraganglioma, rare tumors that can produce excess stress-related hormones, using anonymized electronic health records. Compared with matched adults who had essential hypertension, those with these tumors had higher rates of fatty liver disease, serious liver complications and some cardiovascular outcomes over several years. Because this was an observational study, it shows associations rather than proving that the tumors caused these outcomes.
Researchers studied 2,632 women from a Finnish birth cohort to examine whether being classified as climacteric at age 46 was associated with anxiety, depression symptoms, and psychiatric medication purchases. Climacteric women had higher reported levels of some anxiety and depression symptoms than preclimacteric women, although this observational study cannot show that menopausal changes caused those symptoms.
